Brought to you by 
Toyama Chemical gets Japanese rights to Cempra's solithromycin
21 May 2021
Executive Summary
Antibiotics developer Cempra Inc. has licensed Toyama Chemical Co. Ltd. (majority owned by Fujifilm Holdings Corp.) exclusive rights to develop and commercialize in Japan its solithromycin (CEM101)--or any product that incorporates the active pharmaceutical ingredient--for all indications except ophthalmic.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Toyama Chemical gets Japanese rights to Cempra's solithromycin
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice